Roche Holding AG’s Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc.’s Xalkori with fewer side effects, according to trial results.
A targeted drug being developed by Pfizer Inc. held advanced lung cancer in check longer than AstraZeneca’s Iressa in newly diagnosed patients, but with a higher rate of side effects, according to data.
Merck KGaA struck a deal worth up to €1 billion to acquire five bispecific immuno-oncology antibodies from F-star Alpha.
Investors Sigh With Relief as bluebird bio, Celgene’s CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free
Although a lot of attention went to unexpected data by China’s Nanjing Legend Biotech, bluebird bio and Celgene had CAR-T data of their own to brag about.
Loxo Oncology Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It
Shares of Loxo Oncology rocketed up more than 48 percent after the company unveiled data from three trials that showed treatment with larotrectinib helped nearly three-quarters of patients battling a variety of cancers.
Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca’s Lynparza versus standard chemotherapy, according to a late-stage trial.
Pfizer defeated an effort to revive 300+ lawsuits alleging that its antidepressant Zoloft causes cardiac birth defects in children when taken by women during early pregnancy.
A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success.
Endocyte announced the cutting of 40 percent of its workforce as the company recalibrates two clinical programs, EC1169 and EC1456.
Elated Bristol-Myers Squibb, Seattle Genetics Rewrite Agreement to Push Promising Drug Combo Into Phase III
Six months after touting positive data from a Phase I/II combination study of Opdivo and Adcetris in patients with relapsed or refractory classical Hodgkin lymphoma at the American Society of Hematology, Bristol-Myers Squibb and Seattle Genetics are plowing forward into a Phase III trial.